Assess whether the primary endpoint will survive FDA scrutiny (d03746)

SITUATION CMC change-control owner is responsible for the primary endpoint will in a mid-size sponsor after a complete response letter, using scientific-advice briefing book as the only working extract. A DSMB note on an imbalance that is not yet a signal is what reset the timeline for this Pharma & Life Sciences Pharmacovigilance file.

DECISION CMC change-control owner in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; scientific-advice briefing book already has the discriminator after a DSMB note on an imbalance that is not yet a signal. 2. Keep Pause the pathway in force until scientific-advice briefing book is completed after a DSMB note on an imbalance that is not yet a signal for CMC change-control owner. 3. Treat scientific-advice briefing book as Escalate safety review because both readings appear after a DSMB note on an imbalance that is not yet a signal. 4. Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the decision the primary endpoint will turns on in scientific-advice briefing book.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 2. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a DSMB note on an imbalance that is not yet a signal. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read scientific-advice briefing book against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move the primary endpoint will for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (scientific-advice briefing book after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for CMC change-control owner in a mid-size sponsor after a complete response letter.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in scientific-advice briefing book, then the action for CMC change-control owner - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Regulatory or exam hook Pharmacovigilance would cite - Pharmacovigilance finding in scientific-advice briefing book that a second reviewer can re-perform